United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,202,400.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $334.00, for a total transaction of $1,202,400.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $43,420. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Up 0.5 %

Shares of NASDAQ:UTHR opened at $338.22 on Friday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $343.98. The company has a 50 day moving average of $303.01 and a 200-day moving average of $257.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The stock has a market cap of $15.00 billion, a price-to-earnings ratio of 15.99, a P/E/G ratio of 1.47 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s revenue was up 33.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.86 EPS. On average, sell-side analysts forecast that United Therapeutics Co. will post 24.87 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on UTHR. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. UBS Group raised their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. Oppenheimer raised their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. Finally, Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $330.64.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of UTHR. V Square Quantitative Management LLC acquired a new position in United Therapeutics during the second quarter valued at approximately $30,000. Rise Advisors LLC bought a new stake in shares of United Therapeutics in the first quarter worth $32,000. GAMMA Investing LLC bought a new stake in shares of United Therapeutics in the fourth quarter worth $43,000. Benjamin F. Edwards & Company Inc. lifted its position in shares of United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares in the last quarter. Finally, Janiczek Wealth Management LLC lifted its position in shares of United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 84 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.